Inhibitex (INHX), which more than doubled on Friday thanks to positive trial data for its...

|By:, SA News Editor

Inhibitex (INHX), which more than doubled on Friday thanks to positive trial data for its hepatitis C drug, gains another 12% premarket after Deutsche lifts its PT to $15 (75% above Friday's close), arguing the trial data will help drive market share gains, and additional positive data could act as new catalysts.